EXHIBIT 31.1



CERTIFICATION OF THE PRINICPAL EXECUTIVE
OFFICER AND PRINCIPAL FINANCIAL OFFICER



Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002

and Securities and Exchange Commission Release
34-46427



I, Graciela Moreno, certify that:



1.
I have reviewed this Annual Report on Form 10-K of Med-Cannabis Pharma, Inc. for the fiscal year ended December 31, 2014;



2.
Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;



3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;



4.
The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:



a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made
known to us by others within those entities, particularly during the period in which this report is being prepared;



b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;



c)
Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and



d)
Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the
registrant’s most recent fiscal quarter (the Registrant’s fourth quarter in the case of an Annual Report) that has
materially effected, or is reasonably likely to materially effect, the registrant’s internal control over financial reporting.



5.
The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the Registrant’s auditors and the audit committee of Registrant’s board of directors
(or persons performing the equivalent functions):



a)
all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting
which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial
information; and



b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting.





|             | MED-CANNABIS PHARMA, INC.               
|------------ | ----------------------------------------
|             |                                         
|May 14, 2015 | /s/ Graciela Moreno                     
|             |                                         
|             | Graciela Moreno                         
|             | President, Chief Executive Officer,     
|             | Principal Executive Officer, Treasurer, 
|             | Secretary, Principal Financial Officer, 
|             | and Director (Sole Officer and Director)